OVERVIEW OF ACTIVITY
Lung cancer is one of the most rapidly evolving fields in oncology nursing and is a major public health concern, with more than 228,000 new cases and 160,000 deaths from metastatic lung cancer estimated to have occurred in the United States during 2013. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with lung cancer, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with lung cancer. Upon completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.
PURPOSE STATEMENT
To present the most current research developments in lung cancer and to provide the perspectives of a nurse practitioner and clinical investigator on the diagnosis and treatment of lung cancer.
LEARNING OBJECTIVES
- Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of lung cancer, including tyrosine kinase inhibitors (TKIs), chemotherapy regimens and targeted biologic treatments.
- Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
- Establish an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer (NSCLC).
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with lung cancer.
ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
FOR SUCCESSFUL COMPLETION
This is an audio CNE program. The participants should listen to the audio MP3s.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Spigel — Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Ms Eaby-Sandy — Consulting Agreements: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Speakers Bureau: Amgen Inc, Genentech BioOncology, Lilly.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation and Genentech BioOncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: February 2014
Expiration date: February 2015
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.